These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31128566)

  • 1. Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women.
    Johansson L; Sacuiu S; Kern S; Guo X; Zetterberg H; Blennow K; Zettergren A; Skoog I
    Neurobiol Aging; 2019 Aug; 80():111-115. PubMed ID: 31128566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: A 25-Year Follow-Up Study.
    Johansson L; Kern S; Zetterberg H; Blennow K; Börjesson-Hansson A; Rosengren L; Guo X; Skoog I
    Dement Geriatr Cogn Disord; 2018; 46(1-2):90-99. PubMed ID: 30145588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
    Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
    Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
    Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer's and other neurodegenerative diseases.
    Halbgebauer S; Steinacker P; Riedel D; Oeckl P; Anderl-Straub S; Lombardi J; von Arnim CAF; Nagl M; Giese A; Ludolph AC; Otto M
    Alzheimers Res Ther; 2022 Nov; 14(1):175. PubMed ID: 36419075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders.
    Delaby C; Alcolea D; Carmona-Iragui M; Illán-Gala I; Morenas-Rodríguez E; Barroeta I; Altuna M; Estellés T; Santos-Santos M; Turon-Sans J; Muñoz L; Ribosa-Nogué R; Sala-Matavera I; Sánchez-Saudinos B; Subirana A; Videla L; Benejam B; Sirisi S; Lehmann S; Belbin O; Clarimon J; Blesa R; Pagonabarraga J; Rojas-Garcia R; Fortea J; Lleó A
    Sci Rep; 2020 Jun; 10(1):9161. PubMed ID: 32514050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
    Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
    JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis.
    Day GS; Yarbrough MY; Körtvelyessy P; Prüss H; Bucelli RC; Fritzler MJ; Mason W; Tang-Wai DF; Steriade C; Hébert J; Henson RL; Herries EM; Ladenson JH; Lopez-Chiriboga AS; Graff-Radford NR; Morris JC; Fagan A
    Neurology; 2021 May; 96(20):e2546-e2557. PubMed ID: 33795390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.
    Pereira JB; Westman E; Hansson O;
    Neurobiol Aging; 2017 Oct; 58():14-29. PubMed ID: 28692877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients.
    Jakobsson J; Bjerke M; Ekman CJ; Sellgren C; Johansson AG; Zetterberg H; Blennow K; Landén M
    Neuropsychopharmacology; 2014 Sep; 39(10):2349-56. PubMed ID: 24694925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?
    Eratne D; Loi SM; Walia N; Farrand S; Li QX; Varghese S; Walterfang M; Evans A; Mocellin R; Dhiman K; Gupta V; Malpas CB; Collins S; Masters CL; Velakoulis D
    Aust N Z J Psychiatry; 2020 Jan; 54(1):57-67. PubMed ID: 31220922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid neurofilament light chain as a biomarker of neurodegeneration in the Tg4510 and MitoPark mouse models.
    Clement A; Mitchelmore C; Andersson DR; Asuni AA
    Neuroscience; 2017 Jun; 354():101-109. PubMed ID: 28461218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Visinin-Like Protein-1 in the Pathophysiology of Alzheimer's Disease.
    Groblewska M; Muszyński P; Wojtulewska-Supron A; Kulczyńska-Przybik A; Mroczko B
    J Alzheimers Dis; 2015; 47(1):17-32. PubMed ID: 26402751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.